

INDEX TO VOLUME 26

AUTHOR INDEX


Abdel-Azim, S., 193
Ali, M.Y., 65
Allonen, H., 29, 113
Andersch, B., 211
Anderson, N.B., 229
Andersen, R.F., 229
Araki, R., 221
Assandri, A., 165
Åstedt, B., 147
Aznar, R., 475
Bamji, M.S., 607
Barthololeyns, J., 535
Bernstein, G.S., 443
Bernstein, R., 443
Beyler, S.A., 137
Bouclier, M., 535
Bredesgaard, P., 229
Bremser, H.-J., 303
Brenner, P.F., 261
Burns, J.W., 521
Cameron, E.D., 121
Casslén, B., 147
Cekan, S.Z., 545
Channing, C.P., 617
Clark, V.A., 443
Coan, C., 443
Coulson, A.H., 443
Covey, D.C., 595
Craig, S., 347
Cullberg, G., 229
Díaz, J., 221
Díaz, M.M., 221
Diezfalussy, E., 545, 567
El-Sharkawy, M.M., 65, 75
Elstein, M., 121
Ernerot, H., 229
Fanøe, E., 229
Farag, R.S., 645
Fathalla, M.F., 65, 75
Faúndes, A., 221
Fayad, M., 193
Fotherby, K., 51
Fraser, I.S., 321, 361, 373, 389
Frezieres, R., 443
Friel, P., 521
Fylling, P., 229, 279
Gallegos, A.J., 475
Galliani, G., 165
Gamble, V.M., 97
Ganguly, T., 635
Ghaneimah, S.A., 65, 75
Giridharan, N., 607
Glinsukon, T., 625
Goodpasture, J.C., 521
Graham, S., 323, 373
Grant, A.M., 165
Graves, Z.R., 59
Haack-Sørensen, P.-E., 229
Hahn, D.W., 617
Hammad, W.A., 65, 75

CONTRACEPTION

Heikkilä, M., 245, 465
Hepburn, S., 347
Hofman, A., 205
Hümpel, M., 83
Hurst, P.R., 97, 159
Ibrahim, M.H., 645
Johannisson, E., 567
Kilzer, L.H., 443
Klottrup, P., 229
Koetsawang, S., 51
Kuhl, H., 303
Kurkulos, M., 59
Lähteenmäki, P., 245
Lancini, G., 165
Landgren, B.-M., 545, 567
Lauersen, N.H., 59
Laurence, K.A., 595
Leavesley, G., 417
Lee, C.-P., 515
Leeds, L., 59
Leepipatpaiboon, S., 487
Lerner, L.J., 165
Liao, W.C., 65, 75
Lindholm, K., 147
Lozano, M., 475
Luukkainen, T., 29, 113, 245, 465
Marrs, R.P., 261
Masironi, B., 567
McCafferty, E., 121
Milsom, I., 211
Mishell, D.R., Jr., 261
Nagib, A.M., 645
Nagui, A.R., 193
Nakamura, R.M., 443
Needleman, S.W., 317
Nielsen, N.-C., 29, 113
Nillius, S.J., 457
Nock, P.E., 165
Nuttall, I.D., 121
Nygren, K.-G., 29, 113
Nylander, P., 465
Ohlsson, K., 147
Omodei-Salè, A., 165
Pakrashi, A., 635
Parks, W.M., 317
Pastene, L., 221
Pedersen, J.H., 229
Pedrón, N., 475
Peplow, P.V., 97, 159
Peugvicha, P., 625
Phillips, A., 617
Piyachaturawat, P., 625
Porter, J., 417
Pyörälä, T., 29, 113
Robins, J., 285
Roy, S., 261
Russowsky, M., 41
Saksena, S.K., 181
Salim, T.H., 65, 75
Samsioe, G., 229
Sandager, T., 229
Sankaram, A.V.B., 607
Sartoretto, J.N., 41
Schmidt, F., 295
Seth, J., 121
Shaaban, M.M., 65, 75
Shaarawy, M., 193
Shi, S., 545
Simeock, B.W., 323
Siriwongse, T., 487
Skarin, G., 457
Smith, G.C., 443
Smith, S.C., 65, 75
Snidvongs, W., 487

CONTRACEPTION

Surrago, E.J., 285
Swyer, G.I.M., 23
Tang, F., 515
Tantayaporn, P., 487
Tatum, H.J., 295
Taubert, H.-D., 303
Thiery, M., 295, 505
Tsang, A.Y.F., 515
van Vliet, H.C.A.M., 205
Vermeulen, A., 505
von Dadelszen, P., 159
Wang, E., 545
Weisberg, E., 361, 389
Wheeler, R., 521
WHO Task Force on Female
 Sterilization, 587
WHO Task Force on Intrauterine
 Devices for Fertility Regulation, 1
Wide, L., 457
Wong, P.Y.D., 515
Youssef, A.M., 645
Zaneveld, L.J.D., 137, 521



INDEX TO VOLUME 26
SUBJECT INDEX

Abortifacient effect,
 D-Ser(TBU)⁶-EA¹⁰-LRH, 457
 piperine (mouse), 625

Abortifacient results, 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository
 for termination of early gestation, 261

Abortion, effects on subsequent reproduction, 389

Abortion rate, PGE₂ vaginal suppository for midtrimester pregnancy termination, 285

Absorption in animals, norethisterone, 83

Acid phosphatase activity in uterus, effect of aristolic acid (mouse), 635

Aerosin inhibitors, antifertility activity (mouse), 137

Acute toxicity, 4-methylumbelliferone-4-guanidinobenzoate (mouse), 137

Advantages, using spermicides with barriers, 347

Albumin/globulin ratio, effect of antibilharzial and contraceptive drugs (rat), 645

Alkaline phosphatase,
 effect of antibilharzial and contraceptive drugs (rat), 645
 effect of ethinylestradiol+levonorgestrel in women with active schistosomiasis, 75
 effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

Alkaline phosphatase activity in uterus, effect of aristolic acid (mouse), 635

Alpha-1 antitrypsin,
 effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

4-Aminobenzamidine, antifertility activity (mouse), 137

Anaesthesia, effect on duration of operation and length of incision for post-partum
 sterilization, 495

Antibilharzial drugs and ethinyl oestradiol + d-norgestrel, effect on liver function
 (rat), 645

Antibody response when immunized with β -hCG coupled to tetanus toxoid, effect of
 carrier preimmunization (rabbit), 595

Antifertility activity,
 DL III (baboon), 165
 piperine (mouse), 625
 systemically administered proteinase (acrosin) inhibitors (mouse), 137

CONTRACEPTION

- Antifibrinolytic agents, release rate from ethylene-vinyl acetate matrix, 521
- Aristolic acid, effect on uterine phosphatase levels during early pregnancy (mouse), 635
- Aristolic acid + progesterone, effect on uterine phosphatase levels during early pregnancy (mouse), 635
- Barrier methods, fertility following discontinuation, 389
- Barrier methods and spermicides, use in disabled people, 417
- Barrier methods of contraception,
 - effectiveness with and without spermicide, 347
 - use among young Swedish women, 211
- Benzamidine, antifertility activity (mouse), 137
- Bilirubin,
 - effect of ethinyl estradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
- Bioavailability in animals, norethisterone, 83
- Biotransformation and pharmacokinetics in animals, norethisterone, 83
- Bleeding and spotting,
 - levonorgestrel-releasing IUD, 245, 465
 - Nova-T, 245, 465
- Bleeding pattern,
 - effect of ethinyl estradiol + levonorgestrel, 121, 545
 - effect of levonorgestrel-releasing IUD, 465
 - effect of Nova-T, 465
 - effect of vaginal device releasing levonorgestrel, 567
 - effect of vaginal device releasing norethisterone, 567
- Cadmium chloride, effect on ovulation, egg transport and pregnancy (rabbit), 181
- Carcinogenesis, progestogen-only mini-pill, 373
- Carrier preimmunization, effect on neutralizing antibody response when immunized with β -hCG coupled to tetanus toxoid (rabbit), 595
- Catechol estrogens and thrombosis, 317
- Catechol-O-methyltransferase, effect of gossypol (rat), 515
- Catechol-O-methyltransferase inhibition by gossypol, effect of plasma proteins (rat), 515
- Cavity Rim cap, studies of cervical caps, 443
- Ceruloplasmin,
 - effect of ethinylestradiol+levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

CONTRACEPTION

- Cervical barrier,
 - effectiveness, 347
 - instructions for use by family planning authorities, 347
- Cervical caps, vaginal lesions associated with use, 443
- Cervical mucus, effect of ethinyl estradiol + levonorgestrel, 121
- Cervical priming, 15-ME-PGF_{2 α} prior to IUD insertion, 59
- Choice of device, IUD use in nulliparous women, 323
- Cholesterol,
 - effect of ethynodiol + desogestrel, 229
 - effect of levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 - effect of triphasic ethynodiol + 1-norgestrel, 505
 - effect of triphasic ethynodiol + levonorgestrel, 229
- Clinical study, Lippes loop C and T-Cu 380A, 221
- Closure,
 - levonorgestrel-releasing IUD, 245
 - Nova-T, 245
- Combined oestrogen-progestogen oral contraceptives, fertility following discontinuation, 389
- Comparative study,
 - culdoscopy and minilaparotomy for surgical contraception, 587
 - Nova T and Copper T 200, 29
- Comparative trial, interval IUD insertion in parous women, 1
- Complication,
 - 9-deoxy-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for termination of early gestation, 261
 - IUD use in nulliparous women, 323
 - PGE₂ vaginal suppository for midtrimester pregnancy termination, 285
- Complications and complaints,
 - culdoscopy for surgical contraception, 587
 - mini-incision for post-partum sterilization, 495
 - minilaparotomy for surgical contraception, 587
- Condition of newborn,
 - pregnancy after removal of Copper T 200, 113
 - pregnancy after removal of Nova T, 113
- Condom,
 - effectiveness, 347
 - instructions for use by family planning authorities, 347

CONTRACEPTION

Continuation rate,
 Lippes loop C, 221
 progesterogen-only mini-pill, 373
 T-Cu 380A, 221

Contraception and pregnancy, among young Swedish women, 211

Contraception in disabled people, 417

Contraceptive counselling for disabled people, 417

Contracestational profile, DL III (baboon), 165

Conversion of precursors into norethisterone in animals, 83

Copper 7,
 effect on hemoglobin levels, 475
 menstrual blood loss estimates, 475
 randomized multicentre comparative trial, 1

Copper dissolution rate, effect of mineral deposits on TCu220C, 295

Copper loss from TCu220C, 295

Copper T 200,
 comparative study, 29
 return of fertility after removal, 113

Cortisol,
 effect of ethynodiol diacetate + mestranol, 193
 effect of triphasic ethinylestradiol + 1-norgestrel, 505

Cortisol metabolism and correlation to depression, ethynodiol diacetate + mestranol, 193

Culdoscopy and minilaparotomy, comparative study for surgical contraception, 587

Cumulative net probabilities of discontinuation, randomized multicentre trial
 of IUDs, 1

Cumulative probability of pregnancy, after removal of IUD, 113

Cumulative rates, comparative study of Nova T and Copper T 200, 29

Cycle control,
 ethinylestradiol + desogestrel, 229
 levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 triphasic ethinylestradiol + levonorgestrel, 229

Cyclicity, effect of porcine follicular fluid (rat), 617

D-Ser(TBU)⁶-EA¹⁰-LRH, abortifacient effect, 457

Dehydroepiandrosterone, effect of triphasic ethinylestradiol + 1-norgestrel, 505

Dehydroepiandrosterone sulphate, effect of triphasic ethinylestradiol + 1-norgestrel, 505

CONTRACEPTION

Delay of Menses Test, 23

Delayed labor, effect of piperine (mouse), 625

9-Deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository, termination of early gestation, 261

Depot-medroxyprogesterone acetate,
effect on progesterone levels when administered on various cycle days, 487
fertility following discontinuation, 389
use in disabled people, 417

Depression and serotonin metabolism, effect of ethynodiol diacetate + mestranol, 193

Development and evaluation of inhibitor-releasing matrix for IUDs, 521

Disability and reproduction, 417

Disabled people, sexuality, fertility and contraception, 417

Disadvantages, using spermicides with barriers, 347

Discontinuation,
ethynodiol + desogestrel, 229
levonorgestrel followed by ethynodiol + norgestrel, 41
randomized multicentre trial of IUDs, 1
triphasic ethynodiol + levonorgestrel, 229

Discontinuation of oral contraception, reasons among young Swedish women, 211

Dissolution rate of copper, effect of mineral deposits on TCu220C, 295

DL III (3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4 triazole)

DL III plasma levels, after administration (baboon), 165

Early gestation termination, 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository, 261

Early pregnancy, effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457

Ectopic pregnancy,
after sterilization reversal, 361
following contraceptive use, 389

Effectiveness, barrier methods of contraception with and without spermicide, 347

Efficacy,
administration of Sulprostone for termination of second trimester pregnancy, 279
ethynodiol + desogestrel, 229
progesterone-only mini-pill, 373
triphasic ethynodiol + levonorgestrel, 229

Egg transport, effect of cadmium chloride (rabbit), 181

Endometrial effect, vaginal device releasing levonorgestrel, 567

Enterohepatic circulation in animals, norethisterone, 83

CONTRACEPTION

Estradiol, effect on prostacyclin release, 317

Estradiol level,
 effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457
 effect of ethinyl estradiol + levonorgestrel, 121, 545
 effect of levonorgestrel-releasing IUD, 245
 effect of vaginal device releasing levonorgestrel, 567

Ethinyl estradiol + ethynodiol diacetate, delay of menses, 23

Ethinylestradiol + 1-norgestrel triphasic, metabolic effects, 505

Ethinyl estradiol + levonorgestrel,
 effect on pituitary-ovarian function during normal tablet-taking, 121
 effect on pituitary-ovarian function when tablets are missed, 121
 hormonal consequences of missing the pill, 545
 liver function tests and serum proteins in women with active schistosomiasis, 75
 liver function tests and serum proteins in women with past viral hepatitis, 65

Ethinyl estradiol + norethindrone, delay of menses, 23

Ethinyl estradiol + norethindrone acetate, delay of menses, 23

Ethinyl estradiol + norgestrel, delay of menses, 23

Ethinyl estradiol + norgestrel following levonorgestrel, new approach to oral
 contraception, 41

Ethinyl estradiol level, effect of ethinyl estradiol + levonorgestrel, 121

Ethinylestradiol + desogestrel, efficacy, effect on serum proteins and lipid
 metabolism, 229

Ethynodiol + d-norgestrel and antihelarzial drugs, effect on liver function
 (rat), 645

Ethinylestradiol + levonorgestrel triphasic, efficacy, effect on serum proteins
 and lipid metabolism, 229

Ethylene-vinyl acetate, use as inhibitor-releasing matrix for IUDs, 521

3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4 triazole (DL III),
 contragestational profile (baboon), 165
 kinetic profile (baboon), 165
 non-hormonal antifertility agent (baboon), 165

Ethynodiol diacetate + mestranol, effect on serotonin metabolism and depression, 193

Evaluation of inhibitor-releasing matrix for IUDs, 521

Event rates, IUD use in nulliparous women, 323

Events during four years of use,
 Copper T 200, 29
 Nova T, 29

CONTRACEPTION

Excretion in animals, norethisterone, 83

Expulsion,

- Copper 7, 1
- Copper T 200, 29
- IUD use in nulliparous women, 323
- levonorgestrel-releasing IUD, 245
- Lippes loop C, 221
- Lippes Loop D, 1
- Nova T, 29, 245
- randomized multicentre trial of IUDs, 1
- TCu220C, 1
- T-Cu 380A, 221

Failure rate, PGE₂ vaginal suppository for midtrimester pregnancy termination, 285

Family planning services for disabled people, 417

Ferritin concentration,

- levonorgestrel-releasing IUD, 465
- Nova T, 465

Fertility,

- after abortion induced by DL 111 (baboon), 165
- after removal of IUD, 113

Fertility following discontinuation, review of different methods of fertility control, 389

Fertility following reversal of sterilization, 361

Fertility in disabled people, 417

Fertility post-pill, progestogen-only mini-pill, 373

Follitropin (FSH)

FSH (follicle stimulating hormone or follitropin)

FSH level,

- effect of ethinyl estradiol + levonorgestrel, 121, 545
- effect of levonorgestrel-releasing IUD, 245

Future fertility, IUD use in nulliparous women, 323

Gestation, effect of α -monofluoromethyl histidine (mouse), 535

Glucose, effect of triphasic ethinylestradiol + 1-norgestrel, 505

Glutamic-oxaloacetic transaminase, effect of antibilharzial and contraceptive drugs (rat), 645

Glutamic-pyruvic transaminase, effect of antibilharzial and contraceptive drugs (rat), 645

Gonadotrophin-releasing hormone analogues, fertility following discontinuation, 389

CONTRACEPTION

Gossypol,
 effect on catechol-O-methyltransferase (rat), 515
 effect on testis cytosolic lactic dehydrogenase-X activity (rat), 607
 purification procedure, 607

Gossypol inhibition of catechol-O-methyltransferase, effect of plasma proteins (rat), 515

Haptoglobin,
 effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

HCG (human chorionic gonadotropin)
 β -hCG coupled to tetanus toxoid immunization, effect of carrier preimmunization on neutralizing antibody response (rabbit), 595

HCG level, effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457

β -hCG level, effect of 9-deoxy-16,16-dimethyl-9-methylene PGE₂, 261

HDL (high-density lipoproteins)

HDL-cholesterol,
 effect of ethinylestradiol + desogestrel, 229
 effect of triphasic ethinylestradiol + 1-norgestrel, 505
 effect of triphasic ethinylestradiol + levonorgestrel, 229

Hematological changes,
 levonorgestrel-releasing IUD, 465
 Nova-T, 465

Hemoglobin level,
 Cu-7, 475
 Multiload-250, 475

High-density lipoproteins (HDL), effect of levonorgestrel followed by ethinyl estradiol + norgestrel, 41

Histidine decarboxylase activity, effect of α -monofluoromethyl histidine in foeti and newborn (mouse), 535

Histamine content, effect of α -monofluoromethyl histidine in foeti and newborn (mouse), 535

Histological examination of liver,
 effect of metriphonate (rat), 645
 effect of oxamniquine (rat), 645

Hormonal consequences of "missing the pill", ethinyl estradiol + levonorgestrel, 545

17-Hydroxycorticoid, effect of ethynodiol diacetate + mestranol, 193

2-Hydroxyestradiol, effect on prostacyclin release, 317

5-Hydroxyindole acetic acid, effect of ethynodiol diacetate + mestranol, 193

5-Hydroxyindoles, effect of ethynodiol diacetate + mestranol, 193

CONTRACEPTION

5-Hydroxytryptamine, effect of ethynodiol diacetate + mestranol, 193

Immediate postabortal insertion,
levonorgestrel-releasing IUD, 245
Nova-T, 245

Immediate post-insertion complications, IUD use in nulliparous women, 323

Immunization with β -hCG coupled to tetanus toxoid, effect of carrier preimmunization on neutralizing antibody response (rabbit), 595

Immunological methods of contraception, fertility following discontinuation, 389

Implantation,
effect of indomethacin-loaded IUD (rat), 97
effect of piperine (mouse), 625

Indomethacin-loaded IUD, effect on preimplantation embryo and implantation (rat), 97

Indomethacin-loaded silastic rods, effect on retention of IUD (rat), 159

Infertility following abortion, 389

Infertility following hormonal contraceptive use, 389

Informed consent, fertility control services for disabled people, 417

Inhibition of catechol-O-methyltransferase by gossypol, effect of plasma proteins (rat) 515

Inhibition of testis cytosolic lactic dehydrogenase-X activity, effect of gossypol (rat), 607

Inhibitor-releasing matrix for IUDs, development and evaluation, 521

Initiation to abortion time,
9-deoxy-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for termination of early gestation, 261
PGE₂ vaginal suppository for midtrimester pregnancy termination, 285

Injectable contraception, use in disabled people, 417

Injectable contraceptive,
depo-medroxyprogesterone acetate, 487
medroxyprogesterone acetate, 51
norethisterone enanthate, 51

Injectable hormonal contraceptives, fertility following discontinuation, 389

Insertion of IUD, prior cervical priming with 15-ME-PGF_{2 α} , 59

Insertion techniques, IUD use in nulliparous women, 323

Instructions for use by family planning authorities,
cervical barriers, 347
condoms, 347
spermicides, 347

CONTRACEPTION

Insulin, effect of triphasic ethinylestradiol + 1-norgestrel, 505
Intrauterine delivery of indomethacin from a silastic device (rat), 97
Intrauterine device (IUD),
 Copper 7, 1, 475
 Copper T 200, 29, 113
 development and evaluation of inhibitor-releasing matrix, 521
 effect of indomethacin-loaded silastic rods on retention (rat), 159
 fertility following discontinuation, 389
 indomethacin-loaded silastic rods (rat), 159
 levonorgestrel-releasing, 245, 465
 Lippes loop C, 221
 Lippes Loop D, 1
 Multiload-250, 475
 Nova T, 29, 113, 245, 465
 release of proteolytic enzymes from attached leucocytes, 147
 review of use in nulliparous women, 323
 silastic device incorporating indomethacin (rat), 97
 TCu 200, 147
 TCu200C, 1, 295
 T-CU 380A, 221
 tranexamic acid-releasing, 521
 Trasylol-releasing, 521
 use among young Swedish women, 211
 use in disabled people, 417

In vitro investigations in animals, norethisterone, 83

Iron stores,
 effect of levonorgestrel-releasing IUD, 465
 effect of Nova-T, 465

IUD (intrauterine device)

IUD incorporating indomethacin, effect on preimplantation embryo and
 implantation (rat), 97

IUD insertion, prior cervical priming with 15-ME-PGF_{2 α} , 59

Kinetic profile, DL III (baboon), 165

Kinetics and biotransformation in animals, norethisterone, 83

Lactic dehydrogenase-X activity of testis, effect of gossypol (rat) 607

Lactation, effect of progestogen-only mini-pill, 373

Laminaria, continuous oxytocin infusion and PGE₂ vaginal suppository, midtrimester
 pregnancy termination, 285

CONTRACEPTION

Laminaria and PGE₂ vaginal suppository, midtrimester pregnancy termination, 285

LDL (low density lipoproteins)

LDL-cholesterol, effect of triphasic ethinylestradiol + 1-norgestrel, 505

Lesions observed with Vimule cap, studies of cervical caps, 443

Leucocytes attached to IUDs, release of proteolytic enzymes, 147

Levonorgestrel,

- pharmacokinetic and pharmacodynamic investigations, 567
- review of progestogen-only mini-pill, 373

Levonorgestrel followed by ethinyl estradiol + norgestrel, new approach to oral contraception, 41

Levonorgestrel level,

- effect of ethinyl estradiol + levonorgestrel, 545
- effect of levonorgestrel-releasing IUD, 245
- effect of vaginal device releasing levonorgestrel, 567

Levonorgestrel-releasing IUD,

- body iron stores and patterns of bleeding, 465
- hematologic changes, 465
- immediate postabortal insertion, 245

Levonorgestrel vaginal delivery system,

- endometrial effect, 567
- ovarian effect, 567

LH (luteinizing hormone or lutropin)

LH levels,

- effect of ethinyl estradiol + levonorgestrel, 121, 545
- effect of levonorgestrel-releasing IUD, 245

Lipid metabolism,

- effect of ethinylestradiol + desogestrel, 229
- effect of triphasic ethinylestradiol + levonorgestrel, 229

Lippes loop C, randomized clinical study, 221

Lippes Loop D, randomized multicentre comparative trial, 1

Liver cells,

- effect of metriphonate (rat), 645
- effect of oxamniquine (rat), 645

Liver function, effect of antibilharzial and contraceptive drugs (rats) 645

Liver function tests,

- effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
- effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65

CONTRACEPTION

LRH (luteinizing hormone-releasing hormone)
LRH agonist, D-Ser(TBU)⁶-EA¹⁰-LRH, 457
Lutropin (LH)
Lynestrenol ingestion, serum levels and pharmacokinetics of norethisterone, 303
Male methods of hormonal contraception, fertility following discontinuation, 389
Margin of safety of acrosin inhibitors with respect to fertility (mouse), 137
Mating, effect of porcine follicular fluid (rat), 617
15-ME-PGF_{2 α} (15(S)-15-prostaglandin F_{2 α} methyl ester)
15-ME-PGF_{2 α} vaginal suppository, cervical priming prior to IUD insertion, 59
Mechanisms of action, progestogen-only mini-pill, 373
Medroxyprogesterone acetate, metabolism in obese and thin women, 51
Medroxyprogesterone acetate level, after injection in obese and thin women, 51
Menstrual blood loss,
 Cu-7, 475
 Multiload-250, 475
Menstrual cycle, after abortion induced by DL 111 (baboon), 165
Menstrual cycle changes, progestogen-only mini-pill, 373
Menstrual cycle restoration,
 immediate postabortal insertion of levonorgestrel-releasing IUD, 245
 immediate postabortal insertion of Nova-T, 245
Menstrual cycle stage, effect on serum levels and pharmacokinetics of norethisterone
 after ingestion of lynestrenol, 303
Menstrual hygiene in mental and physical disability, 417
Metabolic effect,
 progestogen-only mini-pill, 373
 triphasic ethinylestradiol + 1-norgestrel, 505
Metabolism of injectable contraceptives in obese and thin women, 51
4-Methylumbelliferone-4-guanidinobenzoate,
 acute toxicity (mouse), 137
 antifertility activity (mouse), 137
Metriphonate,
 effect on liver cells (rat), 645
 effect on liver function (rat), 645
Microsurgery, role in reversal of tubal sterilization, 361
Midtrimester pregnancy termination, PGE₂ vaginal suppository, 287
Mineral deposits on TCu220C, effect on copper dissolution rate, 295
Mini-incision for post-partum sterilization, 495
Minilaparotomy and culdoscopy, comparative study for surgical contraception, 585

CONTRACEPTION

Missed tablets of ethinyl estradiol + levonorgestrel,
 effect on pituitary-ovarian function, 121
 hormonal consequences, 545

α -Monofluoromethyl histidine, effect of gestation (mouse), 535

Multiload-250,
 effect on hemoglobin levels, 475
 menstrual blood loss estimates, 475

National Medical Task Force of the Australian Federation of Family Planning
 Associations, 321

Natural methods of contraception, use in disabled people, 417

4-Nitrophenyl-4-guanidinobenzoate, antifertility activity (mouse), 137

Non-hormonal antifertility agent, DL III (baboon), 165

Norethisterone,
 pharmacokinetics and biotransformation in animals, 83
 review of progestogen-only mini-pill, 373

Norethisterone level,
 after ingestion of lynestrenol, 303
 after injection in obese and thin women, 51
 following administration of norethisterone, 303

Norethisterone levels in animals, after norethisterone administration, 83

Norethisterone minipill, ovarian effect, 567

Norethisterone oenanthate,
 fertility following discontinuation, 389
 metabolism in obese and thin women, 51

Norethisterone pharmacokinetics, after ingestion of lynestrenol, 303

Norethisterone vaginal delivery system, ovarian effect, 567

1-Norgestrel level, effect of ethinyl estradiol + levonorgestrel, 121

Nova T,
 body iron stores and patterns of bleeding, 465
 comparative study, 29
 hematological changes, 465
 immediate postabortal insertion, 245
 return of fertility after removal, 113

Nulliparous women, review of use of IUD, 323

Obese and thin women, metabolism of injectable contraceptives, 51

CONTRACEPTION

- Oestrogen-progesterone combination injectable preparations, fertility following discontinuation, 389
- Operator experience, IUD insertion in nulliparous women, 323
- Oral contraception, use in disabled people, 417
- Oral contraceptive,
 - ethynodiol + ethynodiol diacetate, 23
 - ethynodiol + levonorgestrel, 67, 75, 121, 545
 - ethynodiol + norethindrone, 23
 - ethynodiol + norethindrone acetate, 23
 - ethynodiol + norgestrel, 23
 - ethynodiol + desogestrel, 229
 - ethynodiol + d-norgestrel (rat), 645
 - ethynodiol diacetate + mestranol, 193
 - levonorgestrel followed by ethynodiol + noregestrel, 41
 - review of progestogen-only mini-pills, 373
 - trends in use among Dutch young women, 205
 - triphasic ethynodiol + l-norgestrel, 505
 - triphasic ethynodiol + levonorgestrel, 229
 - use among young Swedish women, 211
- Outcome of pregnancy,
 - after removal of Copper T 200, 113
 - after removal of Nova T, 113
 - among young Swedish women, 211
- Ovarian effect,
 - aristolic acid during early pregnancy (mouse), 635
 - norethisterone minipill, 567
 - vaginal device releasing levonorgestrel, 567
 - vaginal device releasing norethisterone, 567
- Ovarian function, influence of tubal sterilization, 361
- Ovulation,
 - effect of cadmium chloride (rabbit), 181
 - effect of porcine follicular fluid (rat), 617
- Oxamniquine,
 - effect on liver cells (rat), 645
 - effect on liver function (rat), 645
- 17-Oxosteroid, effect of ethynodiol diacetate + mestranol, 193

CONTRACEPTION

Oxytocin infusion, laminaria and PGE₂ vaginal suppository, midtrimester pregnancy termination, 285

Parous women, randomized multicentre trial of IUDs, 1

Pelvic inflammatory disease, IUD use in nulliparous women, 323

Perforation,

- Copper 7, 1
- Lippes Loop D, 1
- randomized multicentre trial of IUDs, 1
- TCu220C, 1

PG (prostaglandin)

PGE₂ vaginal suppository,

- laminaria and continuous oxytocin infusion, midtrimester pregnancy termination, 285
- midtrimester pregnancy termination, 285

PGE₂ vaginal suppository and laminaria, midtrimester pregnancy termination, 285

Pharmacokinetics,

- DL III (baboon), 165
- norethisterone, 303
- norethisterone after ingestion of lynestrenol, 303

Pharmacokinetic and pharmacodynamic investigation, vaginal device releasing levonorgestrel, 567

Pharmacokinetics and biotransformation in animals, norethisterone, 83

16-Phenoxy- ω -tetranor-PGE₂-methylsulfonamide (Sulprostone), termination of second trimester pregnancy, 279

Phosphatase levels, effect of aristolic acid during early pregnancy (mouse), 635

Physical disability and sexuality, 417

Piperine, antifertility activity (mouse), 625

Pituitary-ovarian function,

- effect of ethinyl estradiol + levonorgestrel during normal tablet-taking, 121
- effect of ethinyl estradiol + levonorgestrel when tablets are missed, 121

Porcine follicular fluid,

- effect of post-coital treatment on pregnancy (rat), 617
- effect on ovulation, mating and pregnancy (rat), 617

Postcoital antifertility effect, piperine (mouse), 625

Post-coital treatment with porcine follicular fluid, effect on pregnancy (rat), 617

Post-insertion instructions, IUD use in nulliparous women, 323

Post-partum sterilization, mini-incision, 495

Potency of progestogens in oral contraceptives, Delay of Menses Test, 23

CONTRACEPTION

Precursor conversions into norethisterone in animals, 83

Pregnancy,

- Copper 7, 1
- Copper T 200, 29
- effect of cadmium chloride (rabbit), 181
- effect of porcine follicular fluid (rat), 617
- IUD use in nulliparous women, 323
- levonorgestrel followed by ethinyl estradiol + norgestrel, 41
- levonorgestrel-releasing IUD, 245
- Lippes loop C, 221
- Lippes Loop D, 1
- Nova T, 29, 245
- randomized multicentre trial of IUDs, 1
- TCu220C, 1
- T-Cu 380A, 221

Pregnancy and contraception, among young Swedish women, 211

Pregnancy outcome, among young Swedish women, 211

Pregnancy rate,

- after removal of Copper T 200, 113
- after removal of Nova T, 113

Preimmunization with carrier, effect on antibody response when immunized with β -hCG coupled to tetanus toxoid (rabbit), 595

Preimplantation embryo, effect of indomethacin-loaded IUD (rat), 97

Progeny, gestation after abortion induced by DL III (baboon), 165

Progesterone + aristolic acid, effect on uterine phosphatase levels during early pregnancy (mouse), 635

Progesterone level,

- effect of cadmium chloride (rabbit), 181
- effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 457
- effect of 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 261
- effect of depo-medroxyprogesterone acetate administered on various cycle days, 487
- effect of DL III (baboon), 165
- effect of ethinyl estradiol + levonorgestrel, 121, 545
- effect of levonorgestrel-releasing IUD, 245
- effect of medroxyprogesterone acetate, 51
- effect of norethisterone oenanthate, 51
- effect of vaginal device releasing levonorgestrel, 567

CONTRACEPTION

Progesterone potencies in oral contraceptives, Delay of Menses Test, 23
Progesterone-only mini-pills,
 fertility following discontinuation, 389
 review of clinical studies, 373
Prostacyclin release, effect of 2-hydroxyestradiol and estradiol, 317
Prostaglandin (PG),
 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E₂, 261
 16-phenoxy- ω -tetranor-prostaglandin E₂-methylsulfonamide, 279
 prostaglandin E₂, 285
 15(S)-15-prostaglandin F₂_α methyl ester, 59
Protein content of uterus, effect of aristolic acid (mouse), 635
Proteinase inhibitors, antifertility activity (mouse), 137
Proteolytic enzymes released from leucocytes attached to IUDs, 147
Randomized multicentre comparative trial, interval IUD insertion in parous women, 1
Rate of metabolism,
 medroxyprogesterone acetate, 51
 norethisterone oenanthate, 51
Release rate,
 tranexamic acid from ethylene-vinyl acetate matrix, 521
 Trasylol from ethylene-vinyl acetate matrix, 521
Removal,
 Copper 7, 1
 Copper T 200, 29
 IUD use in nulliparous women, 323
 levonorgestrel-releasing IUD, 245
 Lippes loop C, 221
 Lippes Loop D, 1
 Nova T, 29, 245
 randomized multicentre trial of IUDs, 1
 TCu220C, 1
 T-Cu 380A, 221
Removal of IUD, return to fertility, 113
Reproduction and disability, 417
Retention of silastic IUD, effect of indomethacin incorporation (rat), 159

CONTRACEPTION

- Return of fertility,
 - after removal of IUD, 113
 - effect of DL III (baboon), 165
- Return of menstrual cycle, effect of DL III (baboon), 165
- Return of ovarian activity,
 - medroxyprogesterone acetate, 51
 - norethisterone oenanthate, 51
- Reversal of sterilization, fertility following procedure, 361
- Schistosomiasis, effect of ethinyl estradiol + levonorgestrel in women with active infection, 75
- Second trimester pregnancy termination, administration of Sulprostone, 279
- Selectivity of acrosin inhibitors with respect to fertility (mouse), 137
- Sequential oral contraceptives, fertility following discontinuation, 389
- Serotonin metabolism and depression, effect of ethynodiol diacetate + mestranol, 193
- Serum proteins,
 - effect of antihelminthic and contraceptive drugs (rat), 645
 - effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 - effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
 - effect of ethynodiol + desogestrel, 229
 - effect of triphasic ethynodiol + levonorgestrel, 229
- Sex hormone binding globulin (SHBG),
 - effect of ethinyl estradiol + levonorgestrel, 545
 - effect of ethynodiol + desogestrel, 229
 - effect of triphasic ethynodiol + levonorgestrel, 229
- Sexuality, fertility and contraception in disabled people, 417
- Sexuality and physical disability, 417
- SHBG (sex hormone binding globulin)
- Side effect,
 - administration of Sulprostone for termination of second trimester pregnancy, 279
 - 9-deoxy-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for termination of early gestation, 261
 - effect of ethynodiol + desogestrel, 229
 - effect of levonorgestrel followed by ethinyl estradiol + norgestrel, 41
 - effect of triphasic ethynodiol + levonorgestrel, 229
 - 15-ME-PGF_{2α} vaginal suppository, 59
 - PGE₂ vaginal suppository for midtrimester pregnancy termination, 285

CONTRACEPTION

- Silastic IUD incorporating indomethacin (rat), 97, 159
- Sperm antibodies, role in subsequent fertility following vasovasostomy, 361
- Spermicide with barrier methods of contraception, effectiveness, 347
- Spontaneous abortion,
 - after sterilization reversal, 361
 - following contraceptive use, 389
- Sterilization,
 - comparative study of culdoscopy and minilaparotomy, 587
 - fertility following reversal, 361
 - use in disabled people, 417
- Subcutaneous implant, fertility following discontinuation, 389
- Sulprostome (16-phenoxy- ω -tetranoate-PGE₂-methylsulfonamide)
- Superactive LRH agonist, abortifacient effect, 457
- Surgical contraception, comparative study of culdoscopy and minilaparotomy, 587
- Surgical factors affecting successful reversal of vasectomy, 361
- TCu 200, release of proteolytic enzymes from attached leucocytes, 147
- TCu220C,
 - effect of mineral deposits on copper dissolution rate, 295
 - randomized multicentre comparative trial, 1
- T-Cu 380A, randomized clinical study, 221
- Teratogenesis, following contraceptive use, 389
- Teratogenicity, progestogen-only mini-pill, 373
- Termination,
 - Copper T 200, 29
 - Nova T, 29
- Termination of early gestation, 9-deoxy-16,16-dimethyl-9-methylene PGE₂ vaginal suppository, 261
- Termination of midtrimester pregnancy, PGE₂ vaginal suppository, 285
- Termination of second trimester pregnancy, administration of Sulprostome, 279
- Termination rate,
 - Lippes loop C, 221
 - T-Cu 380A, 221
- Testis cytosolic lactic dehydrogenase-X activity, effect of gossypol (rat), 607
- Testosterone, effect of triphasic ethinylestradiol + 1-norgestrel, 505
- Testosterone-estradiol binding globulin, effect of triphasic ethinylestradiol + 1-norgestrel, 505

CONTRACEPTION

Therapeutic abortion, effect on subsequent reproduction, 389
Therapeutic (safety) index of acrosin inhibitors with respect to fertility (mouse), 137
Thin and obese women, metabolism of injectable contraceptives, 51
Thyroxine, effect of triphasic ethinylestradiol + 1-norgestrel, 505
Time best for insertion, IUD use in nulliparous women, 323
Tissue distribution in animals, norethisterone, 83
Tranexamic acid,
 incorporation into ethylene-vinyl acetate matrix for IUDs, 521
 release rate from ethylene-vinyl acetate matrix, 521
Transaminases,
 effect of ethinylestradiol + levonorgestrel in women with active schistosomiasis, 75
 effect of ethinyl estradiol + levonorgestrel in women with past viral hepatitis, 65
Transcortin,
 effect of ethinylestradiol + desogestrel, 229
 effect of triphasic ethinylestradiol + 1-norgestrel, 505
 effect of triphasic ethinylestradiol + levonorgestrel, 229
Translocation, IUD use in nulliparous women, 323
Trasylol,
 incorporation into ethylene-vinyl acetate matrix for IUDs, 521
 release rate from ethylene-vinyl acetate matrix, 521
Trends in use of oral contraceptives, Dutch young women, 205
Triglycerides,
 effect of antibilharzial and contraceptive drugs (rat), 645
 effect of ethinylestradiol + desogestrel, 229
 effect of triphasic ethinylestradiol + 1-norgestrel, 505
 effect of triphasic ethinylestradiol + levonorgestrel, 229
Triphasic oral contraceptive,
 ethinylestradiol + 1-norgestrel, 505
 ethinylestradiol + levonorgestrel, 229
Tryptophan metabolism and correlation to depression, ethynodiol diacetate + mestranol, 193
Tubal occlusion methods, in relation to reversal of sterilization, 361
Tubal sterilization, influence on ovarian function, 361
Uterine activity, effect of piperine (mouse), 625
Uterine phosphatase levels during early pregnancy, effect of aristolic acid (mouse), 635
Uterus,
 effect of aristolic acid (mouse), 635
 effect of piperine (mouse), 625

CONTRACEPTION

- Vaginal device, releasing levonorgestrel, 567
- Vaginal lesions associated with use of cervical caps, 443
- Vaginal ring, fertility following discontinuation, 389
- Vaginal suppository,
 - 9-deoxy-16,16-dimethyl-9-methylene PGE₂ for termination of early gestation, 261
 - 15-ME-PGF_{2α} for cervical priming prior to IUD insertion, 59
 - PGE₂ for midtrimester pregnancy termination, 285
- Vasectomy reversal, infertility following vasovasostomy, 361
- Vimule cap,
 - studies of cervical caps, 443
 - vaginal lesions observed with use, 443
- Viral hepatitis, effect of ethinyl estradiol + levonorgestrel on liver function tests and serum proteins in past hepatitis women, 65
- Xanthurenic acid, effect of ethynodiol diacetate + mestranol, 193